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ABSTRACT  
Background: Bibliometric analysis highlights key topics and publications which have 
shaped the understanding and management of esophageal cancer (EC). Here the 100 most 
cited manuscripts in the field of EC are analyzed.  
Methods: The Thomson Reuters Web of Science database with the search terms 
'esophageal cancer’ or ‘esophageal carcinoma’ or ‘oesophageal cancer’ or ‘oesophageal 
carcinoma’ or ‘gastroscopy’ was used to identify all English language full manuscripts 
for the study. The 100 most cited papers were further analysed by topic, journal, author, 
year and institution.  
Results: 121,556 eligible papers were returned and the median (range) citation number 
was 406.5 (1833 to 293). The most cited paper focused on the role of perioperative 
chemotherpy in EC (1833 citations). Gastroenterology published the highest number of 
papers (n=15, 6362 citations) and The New England Journal of Medicine (NEJM) 
received the most citations (n=12, 12125 citations). The country and year with the 
greatest number of publications were the USA (n=50), and 1998, 1999 and 2000 (n=7). 
The most ubiquitous topic was the pathology of EC (n=66) followed by management of 
EC (n=54), and studies related to EC prognosis (n=44). 
Conclusion: The most cited manuscripts highlighted the pathology, management and 
prognosis of EC and this bibliometirc review provides the most influential references 
serving as a guide to popular research themes.  
  
INTRODUCTION  
Esophageal cancer (EC) is a significant cause of morbidity and mortality 
worldwide and there is a growing body of evidence encompassing the pathological, 
clinical, oncological, radiological and basic science features of the disease. Advances in 
the global knowledge base continue apace and underpin developments that translate into 
improved treatments and patient survival.  
The establishment of a citation rank list identifies published work that has had the 
greatest intellectual influence [1]. A citation is received when a publication is referenced 
by another peer-reviewed article and work that has the greatest impact on the scientific 
community is likely to be cited many times. Citation analysis involves ranking and 
evaluating an article or journal based on the number of citations it receives. In addition to 
determining the most frequently cited articles, this analysis is also used to rank journals in 
terms of impact [1].  
Many medical specialties have utilized the citation rank analysis to identify the 
most influential papers in their field which includes; trauma and orthopaedic surgery [2], 
plastic surgery [3], general surgery [4] and oncology [5] and gastric cancer [6]. To date, 
no study has been undertaken to determine the most influential papers in the field of 
esophageal cancer. Analysis of these data provides insight into how our understanding of 
esophageal cancer has developed and how this information has changed our management 
of the disease. The aim of this study was to determine the topics and specifically the 
studies that have been most influential related to the improved understanding and 
management of esophageal cancer. 
METHODS  
A search of the Thomson Reuters Web of Science citation indexing database and research 
platform was completed using the search terms ‘esophageal cancer’ or ‘esophageal 
carcinoma’ or ‘oesophageal cancer’ or ‘oesophageal carcinoma’ or ‘gastroscopy’. The 
returned dataset was filtered to include only English language and full manuscripts and 
sorted by number of citations; a method initially developed by Paladugu and colleagues 
[4]. The 100 most cited manuscripts were identified from the large number of 
manuscripts returned. The dataset was then further evaluated examining title, first and 
senior author, institution and department of the first author, topic, year of publication and 
the country of origin. The individual and 5 year impact factors (both for the year 2013) of 
each journal publishing the manuscripts were recorded.  
  
RESULTS  
The Web of Science search returned 121,556 full-length, English language papers. Table 
1 lists the 100 most cited of these papers [7-106]. The number of citations ranged from 
1833 for Cunningham et al (Perioperative chemotherapy versus surgery alone for 
resectable gastroesophageal cancer) [7] to 293 for Orringer & Sloan (Esophagectomy 
without thoractomy) [106]. The oldest manuscript featured in the top 100 was by Wynder 
et al (A study of etiological factors in cancer of esophagus) and published in 1961 [61]. 
The most recent manuscript was published by van Hagen et al (Perioperative 
chemoradiotherapy for Esophageal or junctional cancer) in 2012 [31]. 
The 100 most influential papers were across 32 journals with the number of 
manuscripts per journal ranging from 1 to 15 (table 2). Although Gastroenterology 
published the most papers (n=15 and 6362 citations), The New England Journal of 
Medicine (NEJM) had the most citations (n=12 and 12125 citations). The NEJM also had 
the highest impact factor (54.420) and 5-year impact factor (50.810).  
The country with the greatest number of publications in the top 100 was the 
United States of America (USA) with 50 publications followed by Germany with 10 
publications. The National Cancer Institute Bethesda had the highest amount of citations 
with 5081 and was the highest number of publications in the top 100 with 6 manuscripts 
(table 3).  One author had 3 and 12 authors had 2 first author publications in the top 100.  
 A possible limitation of this type of study is that historical manuscripts may 
accrue a larger number of citations despite lacking the impact of newer publications. To 
control for this, the number of citations were divided by the number of years since 
publication to give a citation rate (table 4) [7, 8, 9, 10, 11, 12, 16, 27, 31, 76]. The citation 
rate for the top 10 manuscripts ranged from 227 for Bang et al (Trastuzumab in 
combination with chemotherapy versus chemotherapy alone for treatment of HER2-
positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, 
open-label, randomised controlled trial) [11] to 69 for Hvid-Jensen et al (Incidence of 
Adenocarcinoma among Patients with Barrett's Esophagus) [76]. USA had the most 
papers in the top 10 citation rate with 4 followed by UK and Australia with 2.  
 Pathology of esophageal cancer was the topic most widely studied with 66 of the 
top 100 papers covering the topic (table 5). Fifty-four manuscripts looked at the 
management of esophageal cancer of which 40 related to surgery.  Forty four papers 
studied the prognostic basis of clinicopathological factor with 34 papers describing 
clinical trials of chemotherapy. Twenty-seven manuscripts were science papers with 18 
relating to the genetic basis of esophageal pathophysiology or management.   
DISCUSSION  
Esophageal cancer is the sixth leading cause of cancer death accounting for 
approximately 400,000 deaths worldwide in 2012 [107]. The identification of etiological 
factors, how genetic aberrations relate to pathogenesis and optimisation of surgery and 
chemotherapy regimens have led to improvements in patient prognostication and 
management. The results of the current study confirm that these topics were highly 
represented with 87 manuscripts of the top 100 influential papers covering these areas. 
Recently published manuscripts had a higher citation rate, which suggests a significant 
influence within the top 100 within the next 5 to 10 years.   
Influential publications are more likely to be cited by the scientific community 
and these citations form the basis of the impact factor. The impact factor of a journal 
quantifies the average citations of the manuscripts published within the journal during a 
specific period. Therefore, journals with a higher impact factor are recognized as being of 
a higher quality and more likely to contain influential publications. Journals with very 
high impact factors (54.42 – 29.35); NEJM, Lancet, JAMA and Nature Genetics only 
represent 17% of all publications in the top 100. Furthermore, the median impact factor 
was 15.69 and 18% of publications were in journals with an impact factor of 5.07 or less. 
A possible explanation for this relates to the novelty of the results. Novelty can be 
classified as relating to science in general or only esophageal cancer. Findings that have 
already been established in other cancers may then be re-established in esophageal 
cancer. These manuscripts are unlikely to be published in high impact scientific journals, 
however, within the context of this study they are likely to be considered influential.    
 On review of the topics covered in the top 100, pathology and management of EC, 
specifically the influence of surgery and chemotherapy on prognosis, were well studied 
accounting for 87 manuscripts. The results of the MAGIC Trial [7] and the ToGA Trial 
[11] had the highest amount of citations and the highest citation rate respectively. 
Furthermore, management (54%), prognosis (44%), clinical trials (34%) and 
chemotherapy (34%) were highly represented in the top 100 manuscripts. The importance 
of these topics is confirmed by their publication in high impact factor journals; NEJM, 
Lancet and Journal of Clinical Oncology. This reflects the growing influence of 
biomarkers and personalized medicine in managing patients with esophageal cancer. 
Surgery remains the mainstay of treatment and the only potential cure for esophageal 
cancer, and it was represented in 40 manuscripts of the top 100. Other topics included 
aetiology (38%), basic science (27%) and genetics (18%). which support the development 
of novel treatments through improved understanding of malignant behavior of cancer 
cells in EC  
Even with advances in surgical techniques and perioperative care, esophageal 
cancer still remains a leading cause of cancer death worldwide [107]. Consequently, there 
has been a greater effort in developing chemotherapeutic agents and the emergence of 
these studies in the top 100 confirms their importance to the scientific community. The 
majority of studies have looked at chemotherapy regimens in the adjuvant setting, 
however approximately a third of studies looked at neoadjuvant chemotherapy and this 
reflects recent developments in the care of patients with EC. The recent heightened 
importance of studies related to chemotherapy is reflected by their publication in higher 
impact factor journals such as NEJM, Lancet and Journal of Clinical Oncology.   
The main limitation of this manuscript is the potential for several types of bias, 
which may affect results. Disproportionate citation may result from institutional bias, 
language biases, self citation or powerful person bias. In addition, older journals may 
receive more citations. Although an attempt to control for this was made by using the 
citation rate index, it may take a number of years for influential manuscripts to accrue 
citations due to the publication lead-time for their citing manuscript. Therefore, recently 
published manuscripts that have reached enough citations for inclusion in the top 100 
have added importance. A further limitation is the inclusion of only first and senior 
authors and the institution of the first author. It is possible that several first authors will 
have co-authored other papers in the top 100 and are therefore under represented in the 
current study format. Finally, using a wildcard search term such as esoph* may have 
identified additional papers and this is also a relative weakness of this study. 
CONCLUSION. The most cited manuscripts highlighted in this study describe the 
pathology, prognosis and management of EC including surgery and regimens that have 
resulted in the contemporary understanding and treatment of EC. Arguably, given the 
perceived relative lack of novelty to the science community in general, 40% of 
manuscripts were published in journals with impact factors of less than 10. In addition to 
providing a reference of what could be considered as the most influential papers in 
esophageal cancer, this work serves as a reference for researchers and clinicians alike as 
to the most popular research themes in esophageal cancer. This study also suggests that 
newer manuscripts have a higher citation rate, which will have a significant impact on the 
top 100 within the next 5 to10 years.   
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